Case Report: Bevacizumab-induced renal-limited TMA and FSGS-like lesions in a kidney transplant recipient
{{output}}
Bevacizumab, an anti-VEGF agent commonly employed in cancer therapy, can induce renal vascular endothelial and podocyte damage by inhibiting VEGF, leading to renal disease. We present a case of nephrotic syndrome and renal insufficiency arising from small inte... ...
